Anebulo Pharmaceuticals, Inc. financial data

Symbol
ANEB on Nasdaq
Industry
Pharmaceutical Preparations
Location
Jfl Capital Management, 1017 Rr 620 S, Suite 107, Lakeway, Texas
State of incorporation
Delaware
Fiscal year end
June 30
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 12.5 % +92.6%
Return On Equity -123 % -66.6%
Return On Assets -109 % -57.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.9M shares +1.17%
Common Stock, Shares, Outstanding 25.9M shares +1.17%
Entity Public Float 9.47M USD -80.9%
Common Stock, Value, Issued 25.9K USD +1.17%
Weighted Average Number of Shares Outstanding, Basic 25.9M shares +1.17%
Weighted Average Number of Shares Outstanding, Diluted 25.9M shares +1.17%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.5M USD -15.1%
General and Administrative Expense 4.96M USD -21.4%
Operating Income (Loss) -9.46M USD +18.5%
Nonoperating Income (Expense) 116K USD -83.8%
Net Income (Loss) Attributable to Parent -9.35M USD +19.1%
Earnings Per Share, Basic 0.57 USD/shares +375%
Earnings Per Share, Diluted 0.57 USD/shares +45.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.15M USD
Assets, Current 5.37M USD
Other Assets, Noncurrent 625K USD
Assets 6M USD -58.5%
Accounts Payable, Current 385K USD -32.6%
Accrued Liabilities, Current 625K USD -32%
Liabilities 1.01M USD -32.2%
Retained Earnings (Accumulated Deficit) -64.1M USD -17.1%
Stockholders' Equity Attributable to Parent 4.99M USD -61.5%
Liabilities and Equity 6M USD -58.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.73M USD -34.1%
Net Cash Provided by (Used in) Financing Activities 6.38M USD
Common Stock, Shares Authorized 50M shares +25%
Common Stock, Shares, Issued 25.9M shares +1.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.73M USD -158%
Deferred Tax Assets, Valuation Allowance 4.69M USD +110%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 4.69M USD +110%
Deferred Tax Assets, Operating Loss Carryforwards 2.87M USD +55.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 69M USD +2.06%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 59.7K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%